Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bringing NGS to the Clinic: What Can We Expect?

Published: Thursday, February 07, 2013
Last Updated: Thursday, February 07, 2013
Bookmark and Share
Dr Elaine Mardis shares her views with IDT on the future of NGS and its role in personalized medicine.

Integrated DNA Technologies (IDT) speaks with Dr Elaine Mardis, an expert in DNA sequencing, institute Co-director, and Director of Technology Development at The Genome Institute (Washington University, St Louis, MO, USA), in the most recent edition of the IDT newsletter DECODED. The interview discusses the rising use of Next Generation Sequencing (NGS), with particular emphasis on its role in cancer care, and reveals how IDT xGen™ Lockdown™ Probes have offered Dr Mardis an effective solution for exome sequencing and target capture in her lab. She also shares her perspective on possible future developments in NGS and the challenges to be overcome before we see its routine implementation in the clinic.

Within the article Dr Mardis refers to the significant potential of NGS for disease detection and monitoring, and the subsequent impact on patient care. She explains, “NGS gives us this great advantage of generating data that is very comprehensive, yet available to us in a very short timeframe”. This extensive, patient specific data is key, particularly for individuals suffering with cancer, as it allows diagnoses and the subsequent implementation of personalized treatment plans based on the genomic make-up of the malignancy. However, such extensive data production also poses a hurdle, placing extreme demands on computational resources and bioinformatics expertise for data analysis and medical interpretation.

Throughout the interview Dr Mardis raises further interesting avenues for the future progression and implementation of NGS in the clinic. To read more, access the complete article in this quarter’s edition of DECODED.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IDT and Ubiquitome Partner to Develop Mobile Ebola Test
Handheld, battery-powered Freedom4 enables rapid field deployment of gold standard molecular test.
Wednesday, December 03, 2014
IDT Shares Tips for Optimizing Target Capture
The article discusses improved target capture methods for increasing reliability of next generation sequencing data.
Friday, October 24, 2014
IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
Summit Partners Makes Growth Equity Investment in IDT
IDT’s founder, Dr. Joseph Walder, will remain the company’s majority owner.
Wednesday, March 19, 2014
IDT Earns ISO 9001:2008 Certification at its European Oligonucleotide Production Headquarters
Worldwide certification of quality systems at all manufacturing operations completed.
Tuesday, April 27, 2010
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!